Evidence map›Paper›PMID 41282550›Full record

ArticleGastroenterology report2025

Chemotherapy alone versus chemotherapy plus targeted therapy as adjuvant therapy for initially unresectable colorectal cancer liver metastases: a multicenter cohort study.

Wenju Chang, Shizhao Zhou, Xu Guan, Donghao Xu, Yu Liu, Wentao Tang, Yang Lv, Xiaorui Qin, Fei Liang, Xiaoying Wang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gastroenterology report, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Wenju ChangDepartment of General Surgery, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian, P. R. China.
Shizhao ZhouDepartment of General Surgery, Huadong Hospital, Fudan University, Shanghai, P. R. China.
Xu GuanDepartment of Colorectal Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.
Donghao XuDepartment of General Surgery, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian, P. R. China.
Yu LiuDepartment of General Surgery, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian, P. R. China.
Wentao TangDepartment of General Surgery, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian, P. R. China.
Yang LvDepartment of General Surgery, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian, P. R. China.
Xiaorui QinDepartment of General Surgery, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian, P. R. China.
Fei LiangDepartment of Biostatistics, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.ORCID https://orcid.org/0000-0002-4184-7844
Xiaoying WangDepartment of Liver Surgery, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.
Li RenDepartment of General Surgery, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian, P. R. China.
Jia FanDepartment of Liver Surgery, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.
Ye WeiDepartment of General Surgery, Huadong Hospital, Fudan University, Shanghai, P. R. China.
Xishan WangDepartment of Colorectal Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.
Jianmin XuDepartment of General Surgery, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian, P. R. China.ORCID https://orcid.org/0000-0001-5441-8240

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: There is no consensus on the adjuvant treatment regimen for patients with colorectal cancer liver metastasis (CRLM) who have achieved successful conversion after surgery. This study aimed to compare the efficacy and safety of chemotherapy alone (CA) versus chemotherapy plus targeted therapy (CT) as adjuvant therapy for CRLM patients. Methods: Initially unresectable CRLM patients who were converted to hepatectomy with no evidence of disease between June 2013 and June 2020 were retrospectively analysed. The baseline characteristics were balanced between the CA and CT cohorts by using 1:2 propensity score matching (PSM). After PSM, disease-free survival (DFS) and overall survival (OS) were evaluated. A comprehensive subgroup analysis compared the efficacy between the cohorts, with DFS and OS assessed by using a stratified log-rank test and summarized by using Kaplan-Meier and Cox proportional hazards methods. Results: After PSM, 66 CA and 132 CT patients were included. DFS and OS were similar between the CA and CT cohorts (median DFS: 8.5 vs 10.8 months; median OS: 51.7 vs 56.5 months; both Conclusion: CT, as adjuvant therapy, effectively reduced intrahepatic and extrahepatic recurrence in initially unresectable CRLM patients. The patients with

Indexed as

adjuvant therapytargeted therapyunresectable colorectal cancer liver metastases

Identifiers

PMID41282550
PMCPMC12630130

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.